Steven C Clifford
Overview
Explore the profile of Steven C Clifford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
8408
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George S, Lynn C, Stankunaite R, Hughes D, Sauer C, Chalker J, et al.
Cancer Discov
. 2024 Dec;
PMID: 39693475
We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and...
2.
Adiamah M, Poole B, Lindsey J, Kohe S, Morcavallo A, Burte F, et al.
Neuro Oncol
. 2024 Oct;
27(1):237-253.
PMID: 39377369
Background: Group 3 medulloblastoma (MBGRP3) represents around 25% of medulloblastomas and is strongly associated with c-MYC (MYC) amplification, which confers significantly worse patient survival. Although elevated MYC expression is a...
3.
Schwalbe E, Lindsey J, Danilenko M, Hill R, Crosier S, Ryan S, et al.
Neuro Oncol
. 2024 Oct;
27(1):222-236.
PMID: 39377358
Background: MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term...
4.
Ghasemi D, Okonechnikov K, Rademacher A, Tirier S, Maass K, Schumacher H, et al.
Nat Commun
. 2024 Oct;
15(1):8597.
PMID: 39366943
No abstract available.
5.
Castle J, Shaw G, Weller D, Fielder E, Egnuni T, Singh M, et al.
Neurooncol Adv
. 2024 Jul;
6(1):vdae091.
PMID: 38946880
Background: Medulloblastoma (MB) is the most common malignant pediatric brain tumor, with 5-year survival rates > 70%. Cranial radiotherapy (CRT) to the whole brain, with posterior fossa boost (PFB), underpins...
6.
Mynarek M, Rossius A, Guiard A, Ottensmeier H, von Hoff K, Obrecht-Sturm D, et al.
Neuro Oncol
. 2024 Jun;
26(11):2113-2124.
PMID: 38835160
Background: Neurocognition can be severely affected in pediatric brain tumor survivors. We analyzed the association of cognitive functioning with radiotherapy dose, postoperative cerebellar mutism syndrome (pCMS), hydrocephalus, intraventricular methotrexate (MTX)...
7.
Bailey S, Andre N, Gandola L, Massimino M, Wheatley K, Gates S, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539574
In the original publication [...].
8.
Keeling C, Davies S, Goddard J, Ramaswamy V, Schwalbe E, Bailey S, et al.
EClinicalMedicine
. 2024 Feb;
69:102469.
PMID: 38374970
Background: Medulloblastoma patients with a sub-total surgical resection (STR; >1.5 cm primary tumour residuum post-surgery) typically receive intensified treatment. However, the association of STR with poor outcomes has not been...
9.
Ghasemi D, Okonechnikov K, Rademacher A, Tirier S, Maass K, Schumacher H, et al.
Nat Commun
. 2024 Jan;
15(1):269.
PMID: 38191550
Medulloblastomas with extensive nodularity are cerebellar tumors characterized by two distinct compartments and variable disease progression. The mechanisms governing the balance between proliferation and differentiation in MBEN remain poorly understood....
10.
Kohe S, Bennett C, Burte F, Adiamah M, Rose H, Worthington L, et al.
EBioMedicine
. 2024 Jan;
100:104958.
PMID: 38184938
Background: The malignant childhood brain tumour, medulloblastoma, is classified clinically into molecular groups which guide therapy. DNA-methylation profiling is the current classification 'gold-standard', typically delivered 3-4 weeks post-surgery. Pre-surgery non-invasive...